Aims: To estimate all–cause mortality in a cohort of people who inject drugs (PWID) over the period 2018—2022 in the two major cities of Greece (Athens and Thessaloniki). Methods: PWID were recruited from two community–based seek–test–treat programs for HCV and HIV infections in Athens and Thessaloniki. Participants provided information on sociodemographic characteristics, injection practices, social security number, access to harm reduction and treatment. Data on the vital status and date of death were identified from the national HCV treatment registry. All–cause mortality rates (CMR) were estimated as well as age–, gender– and calendar–year standardized mortality ratios (SMR). Determinants of mortality were assessed using a Cox proportional–hazards model. Results: Of 2,433 PWID, 243 (10.0%) died over a total of 6,649 person-years (PYs) of follow–up. The CMR [95% confidence interval (CI)] was 3.50 (3.08—3.97) deaths per 100 PYs; 3.03 (2.58—3.57) in Athens and 4.56 (3.74—5.57) in Thessaloniki. An increasing trend in CMR was identified over the period 2018—2022 in Athens (p for trend=0.004). The overall SMR (95% CI) was 17.17 (15.14—19.47) per 100 PYs in the combined cohort; 15.10 (12.85—17.75) in Athens and 21.72 (17.78—26.53) in Thessaloniki. The SMR was particularly increased in younger ages, females, those injecting daily, and HIV–infected PWID. Older age, living in Thessaloniki, Greek origin, homelessness, daily injecting drug use, HIV, and HCV infections were independently associated with all–cause mortality. Conclusion: All–cause mortality among PWID in Greece during 2018—2022 is high with the population in Thessaloniki being particularly affected. The increasing trend in mortality in Athens might be the long–term impact of the pandemic on the health of PWID. Preventive programs such as take-home naloxone distribution and community involvement to increase harm reduction, screening, and uptake of antiretroviral and chronic hepatitis C treatment are urgently needed.

No abstract